FDA Approves First Treatment for Children and Adults with NF1
Author: SpringWorks Therapeutics
Published On: 02/11/2025
In an exceedingly exciting announcement, the Neurofibromatosis Network is elated to announce the first and only drug to treat plexiform tumors in both children and adults with NF1. Developed by our friends and partners at SpringWorks Therapeutics, Gomekli (mirdametinib) is a therapy utilized to manage plexiform tumors in adults with NF1. Showing success in increased tumor volume reduction, this treatment is an important step in our continued mission to find better treatments and a cure for NF.
Want to view archived newsletters? Click Here!
Newsletter
Sign up to receive the latest neurofibromatosis news and information in your inbox!
Subscribe